Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

FDA‑approved noninvasive FFR (FFRct) is covered for intermediate‑risk patients with acute or stable chest pain when CCTA demonstrates 40–90% proximal or mid coronary stenosis, and for stable nonobstructive CAD with persistent ischemic symptoms despite maximally tolerated medical therapy. FFRct should only be performed after a completed and interpreted CCTA, is not appropriate for numerous conditions (including recent MI ≤30 days, intracoronary stent, prior CABG grafts, prosthetic heart valves, suspected acute coronary syndrome, and when stenosis is <40% or >90%), and should not be done in conjunction with stress testing unless CCTA quality is insufficient. Some portions of the source text are ambiguous (truncated wording on certain indications), so specific patient‑selection language should be confirmed against the full policy text.

"FDA‑approved FFRct may be used in intermediate‑risk patients with acute or stable chest pain and no known history of coronary artery disease when CCTA shows 40–90% stenosis in a proximal or mid cor..."